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Abstract
Background: The sex hormone estrogen (E2) is pivotal to normal mammary gland growth and
differentiation and in breast carcinogenesis. In this in silico study, we examined metabolic differences
between ER(+)ve breast cancer cells during E2 deprivation.
Methods: Public repositories of SAGE and MA gene expression data generated from E2 deprived
ER(+)ve breast cancer cell lines, MCF-7 and ZR75-1 were compared with normal breast tissue. We
analyzed gene ontology (GO), enrichment, clustering, chromosome localization, and pathway
profiles and performed multiple comparisons with cell lines and tumors with different ER status.
Results: In all GO terms, biological process (BP), molecular function (MF), and cellular component
(CC), MCF-7 had higher gene utilization than ZR75-1. Various analyses showed a down-regulated
immune function, an up-regulated protein (ZR75-1) and glucose metabolism (MCF-7). A greater
percentage of 77 common genes localized to the q arm of all chromosomes, but in ZR75-1
chromosomes 11, 16, and 19 harbored more overexpressed genes. Despite differences in gene
utilization (electron transport, proteasome, glycolysis/gluconeogenesis) and expression (ribosome)
in both cells, there was an overall similarity of ZR75-1 with ER(-)ve cell lines and ER(+)ve/ER(-)ve
breast tumors.
Conclusion: This study demonstrates integral metabolic differences may exist within the same cell
subtype (luminal A) in representative ER(+)ve cell line models. Selectivity of gene and pathway
usage for strategies such as energy requirement minimization, sugar utilization by ZR75-1
contrasted with MCF-7 cells, expressing genes whose protein products require ATP utilization.
Such characteristics may impart aggressiveness to ZR75-1 and may be prognostic determinants of
ER(+)ve breast tumors.
Background
Breast cancer among other diseases, is a major cause of
mortality in women, worldwide. Phenotypic changes dur-
ing breast cancer progression reflect aberrant gene expres-
sion and pathways supporting deregulated growth. Thus,
it is crucial to understand the events of initiation, transfor-
mation and metastasis using global gene expression
approaches. Public database repositories of global gene
expression data generated from high-throughput gene
expression techniques such as SAGE and microarray (MA)
can be successfully harnessed to gain meaningful insights
to early detection, therapeutic outcome, patient assess-
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ment/survival, and drug development. Parallel to gene
technology, the recently developed biocomputational
tools help to understand the biology of a condition by the
orderly arrangement of gene expression data.
The sex hormone E2 is pivotal to normal mammary gland
growth and differentiation and its effects are directly
related to the initiation and progression of breast cancer
[1]. Targets of E2 associated signaling pathways comprise
of several growth factors, growth factor receptors, extracel-
lular proteins, immediate-early genes, and cell cycle regu-
lators [2,3]. While many of these signaling molecules may
contribute to E2 mediated mammary carcinogenesis,
induction of their genes alone cannot fully explain the
mitogenic effects of E2. Despite the identification of E2
targets by global gene expression studies, metabolic differ-
ences resulting from E2 deprivation of ER(+)ve breast can-
cer cells remain largely unexplored [4-6]. Pathways
operating in ER(+)ve breast cancer cells in their un-
induced state may be crucial determinants of downstream
E2 effects and hence needs to be addressed. In this in silico
study we used global gene expression data to perform bio-
computational analysis to examine genes and pathways
operating in E2 deprived luminal A type ER(+)ve breast
cancer cell lines, MCF-7 and ZR75-1 [7].
Methods
Data processing and statistical analysis of SAGE libraries
Public repositories of gene expression data obtained from
SAGE and MA were used in this study [8,9]. SAGE libraries
were generated from MCF-7 and ZR75-1 cells cultured in
phenol red free medium with charcoal stripped FBS; these
cells represented the 0 h time point (un-induced) of a E2
exposure time course experiment [4,10]. Breast cancer
cells were compared with the NBr library generated from
normal mammary cells purified from reduction mammo-
plasty tissue [11]. Raw sequences from SAGE libraries
were analyzed by the SAGE software 2000 (V4.5) and
extracted tags were compared between NBr and MCF-7
(NBr/MCF-7) and ZR75-1 (NBr/ZR75-1) (Table 1 lists the
SAGE libraries used) [12]. Due to the non-availability of
raw sequences of ZR75-1, data for this library were down-
loaded from NCBI [8]. We used Audic-Claverie, Fisher
and Chi square statistical tests (IDEG6 software) to com-
pare libraries [13]. Data files were annotated with the ref-
erence library (MS Access), further verified with SAGEMap
tool for library annotation, and also compared with Abso-
lute Level Lister (SAGEMap). Using MS Access, we created
five files from two parent files (NBr/MCF-7 and NBr/
ZR75-1). These files were NBr/MCF-7 (366 genes), NBr/
ZR75-1 (367 genes), 77 common genes (MCF-7 and
ZR75-1), 289 genes specific to NBr/MCF-7, and 290 genes
specific to NBr/ZR75-1 respectively (Figure 1a). Regres-
sion analysis was performed to show the relationship
between common genes; chromosomal localization of
common genes was done using MAPviewer [8]. In addi-
tion, 263 differentially expressed genes identified within
the SAGE libraries (advanced query function, MS Access)
were arranged in a cluster by Tree View [14]. Genes whose
expression satisfied the significance (p ≤ 0.05) and fold
change criteria (≥5/≤-5, MCF-7/NBr or NBr/MCF-7 and
ZR75-1/NBr or NBr/ZR75-1) were used. To normalize for
interlibrary count differences, tag counts were converted
to tags per million (TPM) for fold change calculations.
To substantiate our findings in the cell lines, we did mul-
tiple comparisons using the 263 gene dataset. Compari-
son with a basal-like ER(-)ve cell line MDA-MB-435
yielded 215 consensus genes, which were used for cluster
analysis. Comparison between MCF-7 (SAGE) and cycling
MCF-7 cells (MCF-7 NCI, cell isolate from NCI60 cell line
set; MA) yielded 115 consensus genes, which were com-
pared by regression analysis. Due to unavailability of
expression data in SAGE/MA databases for cycling ZR75-1
cells, we could not do such comparison. Finally, we also
compared cell lines and breast tumors (subtypes, ER(+)ve
luminal A and B, ER(-)ve basal tumors, MA database)
using gene set enrichment analysis (GSEA, V2.0) tool. Of
the 228 genes selected by this tool, 163 genes were con-
sensus. In all analyses, the MS Access advanced query
function and manual inspection were used to remove
duplicate genes. These files were used to create new files
with specific file format for each bioinformatics tool.
Table 1: A tabular summary of the publicly available SAGE libraries used for comparative analysis in this study
SAGE Libraries Used No. of Total tags No. of Unique tags
SAGE Breast normal epithelium AP NBr 50512 19190
SAGE Breast carcinoma CL ZR75-1 untreated 32303 3983
SAGE Breast carcinoma CL MCF-7 control 0 h 59877 15401
SAGE_Breast_carcinoma_CL_MDA435C 47270 20080
Total tags 189962 58654
MCF-7 and ZR75-1 cells were compared with NBr. A second comparison was made between MCF-7, ZR75-1, and MDA-MB-435 cells.BMC Cancer 2007, 7:181 http://www.biomedcentral.com/1471-2407/7/181
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GO annotation, Pathway analysis and Gene Set 
Enrichment Analysis (GSEA)
Gene classification based on GO terms identifies gene
families regulating a particular biological process (BP),
molecular function (MF), and cellular component (CC).
DAVID (V2.1), a multifunctional tool, annotates genes by
functional classification and biochemical pathways [15].
Genes were annotated individually, for the common
genes, and also for distinct clusters of differentially
expressed genes. The pathway visualization tool, Gen-
MAPP (V2.0) was used to visualize genes within pathways
[16,17]. Up/down-regulated genes expressed in MCF-7/
ZR75-1 were excluded from GenMAPP analysis unless
they were above or below the fold change cutoff (with
respect to NBr). To correlate the findings in cell lines with
breast tumors, we used the gene enrichment tool, GSEA
for five independently derived gene datasets (cell lines, tis-
sues) [18].
Results
Gene utilization in the Gene Ontology (GO) terms and 
pathways and chromosomal gene localization in MCF-7 
and ZR75-1 cells
ER(+)ve MCF-7 and ZR75-1 cells grown under E2
depleted conditions represent the un-induced state [4,10].
SAGE libraries from breast cancer cells were compared to
Gene compartmentation and distribution in the GO terms and pathways Figure 1
Gene compartmentation and distribution in the GO terms and pathways. (a) Venn diagram showing statistically sig-
nificant genes (p ≤ 0.05, ≥5/≤-5) in MCF-7 and ZR75-1 compared to NBr. MCF-7 had 366 and ZR75-1 had 367 significant genes, 
and 77 genes intersecting between the circles were common. (b) In all the GO terms BP, MF, and CC, the gene distribution 
was higher for MCF-7 cells. Of all GO terms, function MF has the highest gene distribution in both cells. (c) DAVID selected 
109 (30%) of 366 genes for MCF-7 cells, and 88 (24%) of 367 genes for ZR75-1 cells for KEGG's pathways, and the rest 
remained unclassified. The classified genes as shown are distributed in common pathways (oxidative phosphorylation, focal 
adhesion, insulin signaling, ribosome, proteasome, and glycolysis/gluconeogenesis). The steroid biosynthesis (1%), tight junction 
and Wnt signaling (0.8%, not shown) were predicted by DAVID for MCF-7. In ZR75-1 cells, highest gene utilization was seen in 
the oxidative phosphorylation pathway (5.7%), the rest were distributed in the ribosome (10 genes, 2.7%), the pentose phos-
phate (HMS), and proteasome pathways (1.1%) respectively. BIOCARTA pathway selected two other pathways with 35 (9.5%) 
genes, unselected by KEGG's pathway. Of these, 4, (1.1%) genes were involved in the MTA-3 in ER(-)ve breast tumor (more 
prominent in ZR75-1, GSEA), and 3 (0.8%) genes were involved in the glycolysis pathways. (d) GO classification of 77 common 
genes in MCF-7 and ZR75-1. Percent of coverage represents the percent of genes annotated by DAVID to the GO terms, BP, 
MF, and CC. Unclassified genes are not shown.
(c)     MCF-7 
  MCF-7 
ZR75-1
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MCF-7 ZR75-1
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the NBr library (normal breast) and statistically signifi-
cant genes were chosen by fold change and significance
criteria [11]. GO analysis was performed at three levels.
Genes expressed in MCF-7 and ZR75-1 cells, common
genes (77 genes), and genes forming distinct cluster signa-
tures (CS) were annotated to delineate individual, com-
mon, and collective similarities and differences with NBr.
Individual annotation of 355 genes (of 366, MCF-7) and
355 genes (of 367, ZR75-1) by DAVID showed that the
percent of classified gene utilization within the GO terms,
BP, MF, and CC was higher in MCF-7 relative to ZR75-1
cells, although there was a similarity in gene distribution
pattern (Figure 1b, Table 2). For the known pathways,
KEGG's and BIOCARTA, DAVID annotated 109 (30%) of
366 (MCF-7) and 88 (24%) of 367 genes (ZR75-1), which
were distributed in various pathways (Figure 1c). Com-
mon utilized pathways included the ribosome, proteas-
ome, insulin signaling, oxidative phosphorylation/
electron transport, and glycolysis/gluconeogenesis, while
specific pathways utilized by MCF-7 included MAPK, tight
junction, Toll-like receptor signaling, and steroid biosyn-
thesis respectively. ZR75-1 cells also used the pentose
phosphate (HMS) and MTA-3 pathways (Tables 1a,1b, see
additional file 1). The individual highest gene distribu-
tion was seen in the oxidative phosphorylation/electron
transport but not in glycolysis/gluconeogenesis pathways
(Figure 1c). Within the common genes however, there was
decreased similarity in GO terms related to metabolism
(for BP, glucose carbohydrate, glucose/hexose metabo-
lism) and energy (oxidative phosphorylation, BP, NADH
dehydrogenase and reductase activity, for MF, and mito-
chondrial electron transport chain, CC) (Figure 1d; see
additional file 1, Table 1c).
Common genes had good correlation. More genes were
up-regulated (66) compared to the down-regulated (9)
ones and 2 genes had opposite expression (Figures 1, 2,
see additional file 4). For the GO term BP, the highest
gene distribution was seen in physiological, cellular and
cellular physiological processes (~45–62%), followed by
macromolecule metabolism and biosynthetic processes
(~10–50%), while only 5–6% genes were used for sugar
metabolism and protein folding. For MF, genes regulating
catalytic and transporter activities were highest (19–32%)
and 5–18% genes were in other categories. About 38–57%
common genes constituted of the intracellular, organelle,
membrane-bound organelle and cytoplasmic compo-
nents (CC), 5–18% genes were distributed in other cate-
gories, including the mitochondrial electron transport
chain (Figure 1d). Similarities being evident in physiolog-
ical processes (BP), catalytic activity (MF), or the intracel-
lular and organelle components (CC), there were
differences in gene distribution in metabolic processes or
protein folding (BP), in transporter activities and electron
transport functions (MF), and in specific cellular compart-
mental components (CC). This indicated difference in
common gene distribution within the GO terms (Figure
1d). For the up-regulated common genes, most genes (≥
5) were localized to chromosomes 7, 11, 16, 17, 19, and
20. Chromosomes 11, 16 and 19 harbored genes with
highest expression (mostly in ZR75-1). Chromosomes 1,
4, 5, 6, 8, 12, 14, and 17 harbored 9 down-regulated genes
and chromosomes 7 and 19 harbored the 2 oppositely
expressed genes (Figure 2; see additional file 2, Table 2).
Gene expression and GO show distinct cluster signatures 
(CS) in MCF-7 and ZR75-1
Based on differential expression patterns, genes forming
distinct CSs were annotated for GO terms using Cluster
and DAVID tools for 263 significant genes. We identified
six distinct CSs (CS1-CS6), which correlated with genes
distributed in pathways in both cell lines (Figure 3; also
see Figure 1A a,b,c, additional file 3). Among other GO
Table 2: Gene distribution in the individual GO terms
MCF-7 No. of Genes % ZR75-1 No. of Genes %
Process (BP) Physiological Process 238 65.0 Cellular Process 214 58.5
Cellular Process 232 63.4 Physiological Process 210 57.4
Cellular Physiological Process 217 59.3 Cellular Physiological Process 202 55.2
Metabolism 179 48.9 Metabolism 156 42.6
Function (MF) Catalytic Activity 109 29.8 Catalytic Activity 93 25.4
Protein Binding 55 15.0 Protein Binding 47 12.8
Hydrolase Activity 48 13.1 Transporter Activity 40 10.9
Transporter Activity 39 10.7 Hydrolase Activity 29 7.9
Component (CC) Cell 229 62.6 Cell 212 57.9
Intracellular 199 54.4 Intracellular 173 47.3
Organelle 174 47.5 Organelle 155 42.3
Membrane-bound Organelle 143 39.1 Membrane-bound Organelle 131 35.8
The distribution of genes within the individual GO terms was higher in MCF-7 cells compared to ZR75-1, though the pattern of gene distribution 
was similar. % denotes percentage of coverage.BMC Cancer 2007, 7:181 http://www.biomedcentral.com/1471-2407/7/181
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Chromosomal localization of 77 common genes in MCF-7 and ZR75-1 cells Figure 2
Chromosomal localization of 77 common genes in MCF-7 and ZR75-1 cells. (a) Localization of 66 up-regulated 
genes, (b) localization of 9 down-regulated genes, and (c) localization of two oppositely expressed genes (also see Table 2, 
additional file 2). The number of hits (in red) represents the number of genes expressed in each chromosome (denoted in 
blue).
(a)
(c)
(b)BMC Cancer 2007, 7:181 http://www.biomedcentral.com/1471-2407/7/181
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terms, the striking feature of CS1 was a marked down-reg-
ulation of genes controlling immune response, protein
biosynthesis and macromolecule biosynthesis in MCF-7
and ZR75-1 as reflected in the process (BP) and function
(MF) gene utilization. ZR75-1 cells mainly had elevated
gene expression in CS2 for protein import (BP) and
cytokine activity (MF); in addition, ZR75-1 cells also had
elevated expression of genes involved in transport proc-
A cluster of 263 differentially expressed genes depicting distinct expression profiles of MCF-7, ZR75-1, and NBr Figure 3
A cluster of 263 differentially expressed genes depicting distinct expression profiles of MCF-7, ZR75-1, and 
NBr. (a) These genes formed six distinct cluster signatures (CS) between the three SAGE libraries. Each row in the cluster 
corresponds to a SAGE library. Percent coverage of genes within the GO terms in each CS is shown lower to the cluster. In 
the cluster, intense red color correlates with high expression, black indicates low expression, green is negative expression, 
and grey is missing expression (genes and their corresponding Unigene IDs are shown in Figure 1A a, b, additional file 3). (b) 
Graphs highlighting the salient distribution of genes within each of the GO terms, biological process (BP), molecular function 
(MF), and cellular component (CC) in the six distinct CSs (a detailed distribution of genes within the GO terms in each CS is 
shown in Figure 1A c: CS1-CS6, additional file 3). DAVID did not classify any genes for CC in CS2.
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esses and increased growth factor activity in CS2. In CS3,
genes related to protein metabolism were differentially
elevated, whereby ZR75-1 cells had increased gene distri-
bution in protein biosynthesis (MF) as well as in the cel-
lular components related to protein biosynthesis (CC)
relative to MCF-7. On the other hand, in CS4, MCF-7 cells
had a relatively up-regulated gene distribution in energy
related functions (MF) compared to ZR75-1 cells. Collec-
tively taken, physiological, cellular, transport, metabo-
lism, were increased in both breast cancer cells, which was
in agreement with GO distribution in individual and
common genes (Table 2, Figure 1d). In CS5, in contrast to
NBr, breast cancer cells had an increased gene distribution
for physiological and cellular processes, and metabolism
(BP). A decreased gene distribution was seen for oxidative
phosphorylation, transport, apoptosis and nucleic acid
metabolism (ATP/GTP metabolism and synthesis) respec-
tively (BP). For MF, the highest gene distribution was seen
in catalytic activity, protein binding, and transporter activ-
ity and lesser distribution was seen in cytochrome c oxi-
dase and endopeptidase activity. While there was an
increase in gene distribution for intracellular components
including mitochondria, decreased distribution was seen
in the electron transport chain and cellular protein metab-
olism components (CC). In contrast to ZR75-1, CS6 had
up-regulation of genes regulating sugar metabolism (glyc-
olysis/gluconeogenesis) and ATP metabolism in MCF-7
cells (BP), transporter activity (MF) and related cellular
compartments, with the exception of ribosome (CC).
Based on GO term analysis, we compared pathways (elec-
tron transport, glycolysis, proteosome, ribosome) with
fold changes (up/oppositely expressed) of common genes
and cell line specific pathways.
To compare breast cancer cells with different ER status, we
did a cluster of the 263 gene dataset of MCF-7 and ZR75-
1 with a highly aggressive ER(-)ve cell line MDA-MB-435
[19]. Despite the heterogeneity among the consensus
genes, we found a down-regulated expression of genes of
the electron transport chain (complex I, IV, V) and protein
synthesis (genes expressing ribosomal proteins), and up-
regulation of some genes of the glycolytic pathway in the
MDA cells (Figure 1Bi, ii, see additional file 3). Also, the
down-regulation of luminal keratin 18 and NME1 in
MDA cells was similar to ZR75-1, but different from MCF-
7 (Figure 1Biii, see additional file 3). We found no corre-
lation in the 115 consensus genes between the E2
deprived and cycling MCF-7 cells (Figure 1C, see addi-
tional file 3) and were unable to compare with cycling
ZR75-1 cells due to the unavailability of SAGE/MA gene
expression data.
Correlation of gene sets in MCF-7/ZR75-1 with breast 
tumor tissues
To correlate the results in MCF-7 and ZR75-1 cells to
ER(+)ve (luminal A and B) and ER(-)ve basal breast tumor
tissues, we compared eleven gene sets from pathways with
distinct differential gene expression by GSEA analysis.
Despite the differences in cell growth conditions (E2 dep-
rivation), global gene expression techniques (SAGE, MA),
and tissue types (luminal and basal), as shown in the indi-
vidual heat maps, the compared pathways had almost
identical gene enrichment (given by the normalized
enrichment score, NES) and distribution, but different
gene expression between groups (Figure 4a,b; Figure 1D,
see additional file 3). Scores were highest for electron
transport chain, oxidative phosphorylation, and ATP syn-
thesis pathways in all groups; ZR75-1 cells resembled
breast tumors exhibiting low enrichment scores for glu-
cose/gluconeogenesis pathway. In contrast, MCF-7 cells
had higher gene enrichment for sugar metabolism, in
agreement with cluster analysis (CS6, Figure 3). The non-
enriched pathways mainly included breast cancer estro-
gen signaling, electron transporter activity, and proteo-
somal degradation in all groups; cell lines had a down-
regulated immune function and cell adhesion in contrast
to the tumor cells. Enrichment for Wnt signaling and
MTA-3 pathways was relatively identical in all groups.
Individual inspection showed that genes of the electron
transport chain were down-regulated in all groups, but to
a higher degree in tumors compared to cell lines, espe-
cially in basal-like tumor. Genes of the breast cancer estro-
gen signaling pathway were progressively down-regulated
from ZR75-1 to luminal B tumors and in basal tumors
there was a total absence of expression. This trend of gene
expression was also seen for immune function, Wnt sign-
aling, MTA-3, and cell adhesion pathways. A progressively
down-regulated gene expression from cell lines to tumors,
though heterogeneous, was seen in proteosome degrada-
tion and glucose/gluconeogenesis pathways (Figure 4).
While NES and gene expression were similar in luminal
and basal tumors, there were differences in the genes
expressed for pathways such as breast cancer estrogen sig-
naling, immune function, and electron transporter activ-
ity. This could be attributed to the heterogeneity of breast
tumors and to the limited number of consensus genes
chosen by the GSEA tool. Overall, ZR75-1 shared a trend
of similarity with tumors.
Energy production and sugar metabolism
Given the individual similarity of gene distribution for the
electron transport/oxidative phosphorylation pathways,
the percent utilization and the number of up-regulated
genes (19 versus 17 genes) was more in ZR75-1 than MCF-
7 (Figures 1c, 5). In complexes I and III, ZR75-1 up-regu-
lated more genes, and in complex IV, both cells up-regu-
lated 5 genes; among the 3 common genes, MCF-7 cellsBMC Cancer 2007, 7:181 http://www.biomedcentral.com/1471-2407/7/181
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had a higher expression of ATP5D. Gene utilization dou-
bled in MCF-7 cells in complex V compared to ZR75-1 (4
and 2 genes). MCF-7 cells used ATP5A1, ATP5J (10.3 fold)
and SLC25A5/ANT2 (adenine nucleotide translocator 2;
26.2 fold) in complex V. Glucose metabolism was higher
in MCF-7 exhibiting a high glycolysis rate (CS6, Figures
3b, 6a) while ZR75-1 showed conservation (4 versus 7
genes). GAPDH, PGK1 and PGAM1 were common (Fig-
ure 6b); un-induced ZR75-1 highly expressed ALDOA and
GAPDH, whereas E2 induces lower expression [8]. ZR75-
1 cells preferably used the HMS pathway for glucose
metabolism (Figure 6c). Besides MCF-7, ZR75-1 and all
tumors had negative gene enrichment for sugar metabo-
lism (Figure 4).
Ribosome pathway and the proteosomal degradation 
pathway
Though GO terms related to protein biosynthesis and
metabolism was decreased in both cells relative to NBr
(CS1), ZR75-1 had increased gene utilization relative to
Enriched Gene Sets for compared pathways operating in MCF-7 and ZR75-1 cells correlated to ER(+)ve and ER(-)ve breast  tumor tissues Figure 4
Enriched Gene Sets for compared pathways operating in MCF-7 and ZR75-1 cells correlated to ER(+)ve and 
ER(-)ve breast tumor tissues. (a) Unclustered heat map of leading edge subsets in all five groups as analyzed by the GSEA. 
Rows represent gene sets and columns are genes. This matrix is not clustered, but shows the distribution of genes in each of 
the gene sets in MCF-7 and ZR75-1 cells in correlation to the ER(+)ve luminal (A and B) and ER(-)ve basal tumors. (b) 
Enriched gene sets as identified by the GSEA tool. The primary statistic denoting gene enrichment is given by the normalized 
enrichment score (NES), size is the number of genes in the gene set (in a few cases, the actual number of genes analyzed by the 
GSEA tool was different), NOM p-val is the nominal P value. For individual gene expression, refer to the cluster heat map (Fig-
ure 1D, additional file 3).
Gene Sets (MCF-7) Size NES NOM-pvalue
Electron Transport Chain 15 1.417 0.088
ATP synthesis 2 1.042 0.382
Glucose/gluconeogenesis 3 0.883 0.579
MTA3 Pathway 1 0.859 0.729
Oxidative phosphorylation 4 0.814 0.723
Wnt signaling 2 0.726 0.851
Cell Adhesion 4 -0.524 0.981
Electron Transporter Activity 3 -0.706 0.848
Proteosome degradation 5 -0.98 0.465
Immune Function 1 -0.982 0.505
Breast Cancer Estrogen Signaling 9 -1.046 0.373
Gene Sets (ZR75-1) Size NES NOM-pvalue
Electron Transport Chain 15 1.347 0.134
Oxidative phosphorylation 4 1.218 0.235
MTA3 Pathway 1 0.94 0.587
ATP synthesis 4 0.891 0.535
Cell Adhesion 4 -0.622 0.92
Wnt signaling 2 -0.825 0.694
Proteosome degradation 5 -0.918 0.557
Electron Transporter Activity 3 -0.954 0.496
Immune Function 1 -1.112 0.317
Breast Cancer Estrogen Signaling 9 -1.12 0.314
Glucose/gluconeogenesis 3 -1.132 0.314
Gene Sets (Luminal A) Size NES NOM-pvalue
Oxidative phosphorylation 4 2.058 0.002
Electron Transport Chain 15 2.042 0
ATP synthesis 2 1.726 0.004
Immune Function 1 1.157 0.277
Breast Cancer Estrogen Signaling 9 0.909 0.538
MTA3 Pathway 1 0.805 0.777
Wnt signaling 2 0.666 0.907
Cell Adhesion 4 0.641 0.87
Electron Transporter Activity 3 -1.365 0.131
Glucose/gluconeogenesis 3 -1.372 0.121
Proteosome degradation 5 -1.842 0.01
Gene Sets (Luminal B) Size NES NOM-pvalue
Electron Transport Chain 15 2.161 0.002
Oxidative phosphorylation 4 2.041 0
ATP synthesis 2 1.749 0.006
Immune Function 1 1.161 0.247
Breast Cancer Estrogen Signaling 9 0.946 0.518
MTA3 Pathway 1 0.823 0.742
Cell Adhesion 4 0.677 0.861
Wnt signalling 2 0.653 0.925
Electron Transporter Activity 3 -1.301 0.147
Glucose/gluconeogenesis 3 -1.372 0.111
Proteosome degradation 5 -1.865 0.014
Gene Sets (Basal) Size NES NOM-pvalue
Electron Transport Chain 15 2.067 0.008
Oxidative phosphorylation 4 2.054 0.006
ATP synthesis 2 1.73 0.012
Immune Function 1 1.156 0.269
Breast Cancer Estrogen Signalling 9 0.885 0.59
MTA3 Pathway 1 0.804 0.802
Cell Adhesion 4 0.661 0.869
Wnt signaling 2 0.653 0.895
Electron Transporter Activity 3 -1.319 0.133
Glucose/gluconeogenesis 3 -1.337 0.147
Proteosome degradation 5 -1.857 0.01
MCF-7
ZR75-1
Luminal A Tumor
Basal Tumor
Luminal B Tumor
(a) (b)BMC Cancer 2007, 7:181 http://www.biomedcentral.com/1471-2407/7/181
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A GenMAPP view of energy production pathway in MCF-7 and ZR75-1 cells Figure 5
A GenMAPP view of energy production pathway in MCF-7 and ZR75-1 cells. Common genes are denoted by an* 
and significant genes with a fold change of ≥5 and ≤-5 were taken. Genes in the GO list were rearranged with GenMAPP to 
depict electron transport in (a) ZR75-1 and (b) MCF-7 cells.
(a)
(b)
Fold change t5
MCF-7
ZR75-1BMC Cancer 2007, 7:181 http://www.biomedcentral.com/1471-2407/7/181
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MCF-7 cells (CS3, Figure 3). Comparison with other path-
ways showed that the ribosome pathway was distinct
because all 9 genes were up-regulated in ZR75-1, versus all
12 down-regulated genes in MCF-7 (Figure 7). More
genes, including the oppositely expressed common gene
RPS16, were in the 60S, but not in the 40S subunit. In the
proteosome pathway, besides more gene utilization, there
was a difference in genes expressed by MCF-7 from ZR75-
1 (Figures 1c, 8). MCF-7 cells selectively up-regulated 3 of
6 genes encoding for ATPase subunits (PSMC1, 5, 6) and
a single non-ATPase subunit coding gene, PSMD2 in the
19S regulatory subunit versus none in ZR75-1 cells. A sin-
gle gene (19S regulator, a part of the 26S complex) encod-
ing the non-ATPase subunits were up-regulated in MCF-7
(p44S10/PSMD6) and ZR75-1 (PSMB8). In the alpha sub-
unit (20S catalytic core), MCF-7 up-regulated 3 versus 2
genes by ZR75-1, and PSMA7 was common. In the beta
subunit (20S catalytic core), ZR75-1 had a higher expres-
Sugar metabolism pathways in MCF-7 and ZR75-1 cells profiled by GenMAPP Figure 6
Sugar metabolism pathways in MCF-7 and ZR75-1 cells profiled by GenMAPP. Common genes are denoted by an * 
and significant genes with a fold change of ≥5 and ≤-5 were taken. Genes in the GO list were rearranged with the GenMAPP to 
depict the glycolysis/gluconeogenesis pathways in (a) MCF-7, (b) ZR75-1 cells and the (c) pentose phosphate (hexose mono-
phosphate shunt, HMS) pathway in ZR75-1 cells.
 (b) 
   (a) 
  (c) 
MCF-7 ZR75-1 ZR75-1 
Fold change t5
Fold change d-5BMC Cancer 2007, 7:181 http://www.biomedcentral.com/1471-2407/7/181
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sion of PSMB6 (Figure 1Aa, see additional file 3) than
MCF-7. MCF-7 also up-regulated PSMC5, which encodes
for another ATPase subunit and down-regulated HLA-C (-
8.7 fold, presentation by MHC class I) and lid associated
RPN (-11.9 fold). ZR75-1 cells up-regulated H2FZ, which
encodes for a histone family member protein. Compari-
son of the proteosome degradation pathway by GSEA
analysis showed a low gene enrichment score for both cell
lines and breast tumors (Figure 4). Of the 5 consensus
genes, PSMD4 and PSMA7 were highly expressed in cell
lines, but absent in tumors. High PSMB6 expression was
ubiquitous, UBA52 was low to absent, and RPS27A
expression was heterogeneous among the groups (Figure
1D, see additional file 3). In both cells, the fold change
was <5 for PSMD4 and PSMB6 (compared to NBr).
Other individual and common pathways in MCF-7 and 
ZR75-1 cells
Some pathways operating in MCF-7 were MAPK, tight
junction, TGF beta signaling, Wnt signaling, Toll like
receptor, steroid biosynthesis and others (Figure 1c; see
additional file 4, Table 1a and Figures 3, 4, 5). The Wnt
signaling pathway showed a relatively high enrichment by
GSEA analysis in MCF-7 cells similar to luminal and basal
tumors, but not ZR75-1 cells (Figure 4). ZR75-1 cells
highly expressed 4 genes (GAPD, ALDOA, HSPB1, MTA1)
in the MTA-3 (BIOCARTA) pathway (Figure 1c; Table 1b,
see additional file 1; Figure 6, see additional file 4) cells.
However, GSEA analysis selected the HSPB1 gene only in
the MTA-3 pathway for tumors and cell lines; the gene was
down-regulated in luminal and basal tumors (Figure 1D,
see additional data file 3). In the tight junction pathway
claudin4 was highly down-regulated (-92.5) and Rab13
was highly up-regulated (27.8) (Figure 3, see additional
file 4) among the 7 genes used in this pathway. In the ret-
roviral genome replication pathway, IL8 (-43.5) was sig-
nificantly down-regulated in ZR75-1 while MCF-7 down-
regulated TNIP1 (-7.5). Immune function was negatively
enriched in both cell lines (GSEA). Both cells had the
insulin signaling, focal adhesion and ATP synthesis path-
ways (Figure 1d; see additional file 1, Table 1).
The ribosome pathway in MCF-7 and ZR75-1 cells Figure 7
The ribosome pathway in MCF-7 and ZR75-1 cells. (a) All 12 genes in this pathway were down-regulated (GenMAPP) in 
MCF-7. (b) In contrast, all the 9 genes were up-regulated in ZR75-1 cells. The only common gene (*) in the small subunit (40S) 
is RPS16, which was down-regulated (-23.7 fold) in MCF-7 and up-regulated (7.5 fold) in ZR75-1 cells. The up-regulated ribos-
omal genes in ZR75-1 indicate increased protein synthesis in these cells in contrast to MCF-7 cells (also refer to CS3, Figure 
3b).
(a) (b) 
Fold change t5
Fold change d-5
MCF-7 ZR75-1BMC Cancer 2007, 7:181 http://www.biomedcentral.com/1471-2407/7/181
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Discussion
In this in silico study, gene expression and enrichment
analyses, pathways, and chromosomal localization of
genes reflect integral metabolic differences between the
two ER(+)ve luminal A type human breast cancer cell
lines, MCF-7 and ZR75-1 cultured under E2 deprivation
[4,10]. As this study is centered around two well-charac-
terized cell lines, which share substantial global similari-
ties in their transcriptomes with ER(+)ve breast tumors,
we did multiple comparisons to demonstrate similarities
and differences with cell lines and tumors with different
ER status [20].
Comparison of gene expression of MCF-7 and ZR75-1
cells with basal-like ER(-)ve MDA-MB-435 cells or cycling
MCF-7 cells indicate that differences may be a result of ER
status, presence/absence of E2, or global gene expression
techniques (SAGE, MA). Comparison with cycling MCF-7
cells showed opposite expression of certain genes (not
shown), which indicates that gene expression is more
likely a result of the presence/absence of E2 in the growth
environment rather than the use of different gene expres-
sion techniques. When compared to the MDA-MB-435
cells, ZR75-1, but not MCF-7 cells, were found to share
similarity in the selectivity of genes of electron transport
for energy minimization. For genes related to breast can-
cer estrogen signaling, GSEA analysis showed a progres-
sive down-regulation of keratin 18 and NME1 from
luminal A to basal tumors, which also correlated with
ER(+)ve MDA-MB-435 cells; low expression of these genes
correlates to poor prognosis and metastasis [21,22].
ZR75-1 cells also have a low expression of these genes,
indicating a similarity towards the ER(-)ve phenotype.
The MDA cells differed from ZR75-1 cells in having a
down-regulated expression of protein synthesis genes and
an up-regulation of glycolytic genes; however, down-regu-
lation of glycolysis has been observed in a highly aggres-
sive S100A7 transfected MDA-MB-231 cells [23]. While
these differences may be attributed to a different ER status,
it is evident that ZR75-1 cells exhibit some characteristics
of the ER(-)ve phenotype. Comparison by GSEA showed
that all the compared pathways were present in both cell
lines, however, ZR75-1 had a greater overall similarity
with luminal and basal tumors among the consensus
genes.
The proteosomal degradation pathway Figure 8
The proteosomal degradation pathway. The pathway in (a) MCF-7 and (b) in ZR75-1 cells. MCF-7 cells had a higher 
gene usage and selected genes which encode for the ATPase subunit proteins in the 19S regulator (PSMC1, PSMC5, PSMC6), 
versus no change in ZR75-1 cells. PSMA7 (alpha subunit, 20S catalytic core) was the only common gene with an identical fold 
change. The histone family member protein encoding gene, H2FZ was up-regulated in ZR75-1 cells.
Fold change t5
Fold change d-5
MCF-7 ZR75-1
(a) (b)BMC Cancer 2007, 7:181 http://www.biomedcentral.com/1471-2407/7/181
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An interesting facet in these cell lines was the dispropor-
tionate contribution of some chromosomes, such as 11,
16, and 19, harboring some of the highly up-regulated
common genes. Some of these genes are involved in metal
ion binding (PPP1CA), electron carrier and transport
activity (CYBA), ATP binding and nucleotide synthesis
(NME3), oxidative phosphorylation (NDUFA3), and elec-
tron transport (COX6B1) as annotated by DAVID. Inter-
estingly, except for COX6B1, all 3 genes (CYBA, NME3,
NDUFA3) were highly up-regulated in ZR75-1 indicative
of efficient energy utilization. We found that 67–68% of
the common genes were localized to the long arm q in all
chromosomes, among which chromosomes 11, 16, and
19 expressed most genes. The amplification and co-ampli-
fication with other chromosomes of 11q13 region of
chromosome 11 is relatively frequent in breast tumors
and overexpression of CCND1 (cyclin D1) and PPP1CA is
also seen [24,25]. In the q arm in chromosome 11,
CCND1, PPP1CA and 5 other genes contributed to 71%
of genes expressed in this chromosome (Table 2, see addi-
tional file 2). Chromosome 16q suffers frequent loss of
heterozygosity (LOH) in sporadic breast cancer; it
expresses a significant list of genes which negatively relate
to recurrence-free breast cancer survival [26,27]. Chromo-
some 19, on the other hand, suffers frequent LOH in its
short arm p, which may cause de-regulated expression of
more genes in the p arm (this study) [28]. In ZR75-1,
some up/down-regulated genes in other chromosomes
regulating critical functions such as lipid utilization and
binding (FASN, StarD10; chromosomes 17 and 11), ion
transport (ATOX1, chromosome 5), and cell survival
(HSPB1, NF-κB; chromosomes 7, 14) may also impart
aggressiveness to these cells [5,29-32]. Interestingly,
FASN, StarD10, HSPB1, NF-κB were down-regulated in
MDA-MB-435 cells, constituting a major difference with
these ER(+)ve cells. HSPB1, a component of multiple
pathways, was also down-regulated in all breast tumors.
Individual GO and CS GO (CS6) showed prominence for
glucose metabolism in MCF-7 cells. ZR75-1 cells used the
HMS pathway to generate NADPH, which maintains glu-
tathione in a reduced state. Reduced glutathione protects
the intracellular sulfhydryl groups to preserve cellular
integrity from oxidative stress in cancer and may be pro-
tective to the ZR75-1 cells [33]. MCF-7 cells, unlike ZR75-
1 and breast tumors, had a high glycolytic rate, which cor-
related with a high expression of SLC25A5/ANT2 (Com-
plex V, electron transport chain). SLC25A5 imports
glycolytic ATP into mitochondria and the overexpressed
gene promotes aggressiveness, cell survival, and arrests
cell proliferation when inhibited [34]. Increased expres-
sion of ANT2 may be a feature of ER(+)ve breast tumors
with a high glycolytic rate (as MCF-7), and absence of
ANT2 expression in ZR75-1 supports this notion. In the
cell lines, gene utilization in the electron transport chain
was similar in the common genes (Complex I-IV)
although the usage of COXC subunits (Complex IV) and
a higher F1 gene utilization (Complex V) was different in
MCF-7 cells. FI genes encode for mitochondrial ATP syn-
thase subunits, which was consistent with the moderately
increased expression of ATP5D in ZR75-1 cells. In cell
lines and tumors, the electron transport chain/oxidative
phosphorylation pathway had the highest individual gene
utilization and enrichment, although there was decreased
gene similarity in the energy associated GO terms. Given
the dissimilarity of the growth conditions of study for cell
lines (E2 deprivation) with tumors, we found differences
in the individual gene expression of complexes I, IV, and
V respectively. Negative gene enrichment and a progres-
sive down-regulation (total absence of expression in basal
tumors) of genes of the electron transporter pathway from
MCF-7 to tumors (lower in ZR75-1 than MCF-7, CS4)
indicate a common energy conservation strategy.
In contrast to energy conservation, ZR75-1 cells demon-
strated elaborate protein synthesis mechanisms (ribos-
ome pathways, CS3). These cells have an increased
ribosomal gene expression, constituting a major differ-
ence with the MCF-7 cells. Notably, the only common up-
regulated gene, RPS16 in ZR75-1 (down-regulated in
MCF-7) correlates with its overexpression in breast, colon,
prostate, liver, and pancreatic tumors [35,36]. The
increased ribosomal gene expression (and protein synthe-
sis) as seen in ZR75-1 cells, is a feature of invasive and
metastatic breast cancers but not in situ cancers [6]. In the
proteosome pathway, MCF-7 selectively up-regulated
more genes encoding for ATPase subunits (PSMC1, 5, 6)
than the non-ATPase subunit coding genes (PSMD2) in
contrast to none by the ZR75-1 cells. The up-regulation of
only p44S10/PSMD6 (19S non-ATPase subunit) by MCF-
7 is of significance as the encoded protein subunit pos-
sesses ATPase activity and ATP-dependent proteolytic
function and has been shown to have increased copy
number in cutaneous cancers and MCF-7 cells [37]. In
contrast, ZR75-1 up-regulated PSMD8, whose protein has
a non ATP-dependent proteolytic activity [38]. PSMA7,
the gene expressed in common in MCF-7 and ZR75-1,
encodes for the core alpha subunit regulating the tran-
scription factor hypoxia-inducible factor-1α, which pro-
duces hypoxic responses in breast tumors [39]; however,
the absence of PSMA7 expression in luminal and basal
tumors may be indicative of either a heterogeneity of
expression in breast tumors or its specific expression in E2
deprivation. This is also true of PSMD4 whose expression
was absent in tumors, but high in cell lines. Interestingly,
the expression of the ubiquitin (Ub) gene UBA52, whose
protein is a part of the proteoasome/Ub complex, was low
to undetectable in all groups. This indicates down-regu-
lated ATP-dependent degradation of Ub-conjugated pro-
teins in breast tumors; this was in contrast with anBMC Cancer 2007, 7:181 http://www.biomedcentral.com/1471-2407/7/181
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increased ATP/Ub-dependent protein degradation in
renal cancer [40]. However, cell lines and tumors had an
up-regulated expression of PSMB6, whose protein is also
involved in ubiquitin-dependent protein catabolism. The
reason for choice of PSMB6 is unclear in breast cells/
tumor, but high expression is also found in thyroid cancer
although not much is known about its role in carcinogen-
esis [41]. The highly up-regulated gene PSMA4 in MCF-7,
encoding for an immunoproteosome, is involved in the
processing of class I MHC peptides (HLA-C was down-reg-
ulated in MCF-7) and possesses threonine endopeptidase
activity. RPN1 (lid subunit) mediates ubiquitin-like
domain binding to this proteasome for protein amino
acid glycosylation [42]. Down-regulated RPN1 agrees
with decreased protein synthesis (and hence post-transla-
tional modification) in MCF-7 (ribosome pathway).
Interestingly, ZR75-1 cells highly up-regulated H2AFZ
(proteosome pathway), a member of the histone H2A
family and a replication-independent gene [43]. Lack of
H2AFZ is lethal in mouse embryos, hence this gene may
be protective in E2 deprivation for the ZR75-1 cells [44].
MCF-7 cells also mobilized other pathways such as MAPK,
tight junction, TGFβ signaling, Wnt, and shared common
pathways as insulin and focal adhesion signaling path-
ways with ZR75-1. The MAPK pathway is active in breast
and other cancers, and it also activates other pathways
such as the insulin receptors/insulin-like growth factor
receptors (IGFR) pathway [45]. The insulin signaling
pathway influences breast tumor growth, proliferation,
transformation and survival [46]. Moreover, IGF can acti-
vate the ER through the Ras-MAPK pathway and enhance
its transcriptional potential without E2 binding [47]. α-
Catenin/CTNNB1 belongs to the E-cadherin-catenin fam-
ily of adhesion molecules, and it is a key regulator of the
Wnt signaling pathway (and TGFβ signaling pathway).
CTNNB1 links the β/γ-catenin-cadherin complex to the
cytoskeleton to make a functional E-cadherin complex.
Abnormal E-cadherin and CTNNB1 positively correlates
with high grade ductal carcinomas, lymph node metasta-
sis and poor survival [48]. The down-regulated expression
of the transcription factors STAT3 and JUN in the TGFβ
signaling/Wnt pathway indicates a repression of gene
expression of the un-induced MCF-7 cells. P120 catenin
or CTNND1 also belongs to the E-cadherin complex.
Immunodetectable diffuse cytoplasmic localization of
CTNND1 is found in lobular carcinoma, whereas ductal
breast carcinoma retains the dominant membrane immu-
nostaining pattern [49]. In our GSEA analysis, we found
that CTNND1 was ubiquitously expressed in all breast
tumors and MCF-7 and ZR75-1 cells, which made it hard
to discriminate the relation of this gene in the cell lines in
the light of breast tumors we examined. Immunostaining
experiments may discriminate this relationship with pre-
cision. Other low expressing genes included ZYX and
RAC1 (cell lines) and DSCAM expression was absent in
tumors. The expression of claudin4, a tight junction pro-
tein, is highly down-regulated in MCF-7 (-92.5 fold),
which correlates with weak or absence of expression in
grade 1 invasive carcinomas compared to benign breast
epithelia and normal breast [8,50]. Claudin4 protein
potently inhibits invasion and metastasis in pancreatic
cancer cells and therefore a weak/absence of expression in
these invasive cell lines is likely [51]. As seen in invasive
and metastatic tumors, MCF-7 cells highly expressed
Rab13 [6].
Compared to MCF-7 and tumors, GSEA gave a higher
enrichment score for ZR75-1 cells for the ER regulated
MTA-3 pathway, although GSEA predicted the expression
of only one consensus gene, HSPB1 (Hsp27). In this path-
way, as annotated by DAVID, ZR75-1 also had an up-reg-
ulated expression of MTA1, ALDOA, and GAPDH. Besides
the MTA-3 pathway (ZR75-1), HSPB1, an ATP-independ-
ent chaperone with the hsp20-like chaperonedomain,
operates in multiple pathways like the breast cancer estro-
gen signaling pathway (MCF-7, ZR75-1). Functionally,
HSPB1 inhibits heat shock-induced cellular protein syn-
thesis, increases cell survival, and is a crucial component
of oncogenic pathways and it may thus be preferred by
ZR75-1 [31]. The MTA proteins, MTA1-3 are components
of chromatin remodeling pathways [52]. These proteins
form a repressive chromatin complex shutting down the
expression of target genes; expression of MTA proteins
also increases the risk of cancer susceptibility and may
render aggressiveness to the ZR75-1 cells [53]. In the ret-
roviral genome replication pathway (not shown), MCF-7
suppressed TNIP1 (-7.5), but ZR75-1 cells exhibit a greater
immune suppression by significantly down-regulating IL8
(-43.5). This agreed with a lesser enrichment score for
immune function in ZR75-1 cells compared to MCF-7, a
characteristic seen in the aggressive ER(-)ve breast cancer
cells and in basal tumors (this study) [23]. On the other
hand, MCF-7 cells may gain survival advantage by greater
mobilization of the focal adhesion pathway [54].
Relating gene expression to clinical outcome is crucial in
understanding the diversity of breast tumors. Clinically,
patients with ER(+)ve tumors have a favorable prognosis,
even though E2 is a powerful mitogen in receptor-positive
cells. However, even patients within the ER(+)ve subtype
have a different outcome; patients with luminal A subtype
ER(+)ve tumors have a better prognosis and relapse-free
survival compared to those with luminal B or C type [55].
This in silico study is of significance and is translatable to
human biology as the evidence presented here shows that
differences exist between breast cancer cells with similar
ER status (luminal A type) and also for the recent finding
that MCF-7 or ZR75-1 cell lines are good models to iden-
tify important molecular events of ER(+)ve breast tumorsBMC Cancer 2007, 7:181 http://www.biomedcentral.com/1471-2407/7/181
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[20]. Multidirectional computational analyses in cell line
models may thus reflect tumor characteristics which are of
importance in predicting patient outcomes even within a
narrow subset of tumors (example luminal A subtype).
Conclusion
This study shows that ZR75-1 cells selectively use genes
for energy, protein synthesis and sugar metabolism and
other pathways differently from the MCF-7 cells. ZR75-1
cells share characteristics of ER(-)ve breast tumors and
cells in certain respects, such as energy minimization and
sugar requirements. The specific use of pathways (HMS,
ribosome, MTA-3), their down-regulation (immune func-
tion), and gene utilization (FASN, STARD10, HSPB1,
H2FZ, keratin 18, NME1), probably impart more aggres-
siveness to the ZR75-1 than MCF-7. Salient differences in
these ER(+)ve breast cancer cells require further testing,
nevertheless, they may be decisive determinants of treat-
ment outcome and prognosis of ER(+)ve breast tumors.
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